个体化药代动力学指导剂量早期启动羟基脲可使镰状细胞贫血患儿获得持续近全细胞性HbF表达
本研究在镰状细胞贫血(SCA)患儿中采用个体化药代动力学指导方案,以预测最大耐受剂量(MTD)起始羟基脲治疗。结果显示可持续HbF诱导(平均>30%)长达6年,近70%患者F细胞≥80%,近半数≥90%,平均HbF/F细胞含量约12 pg。早期启动和良好依从性与高F细胞反应相关。
要点
- 以预测MTD起始的个体化药代动力学指导羟基脲方案可实现持续HbF诱导。
- 近70%患儿达≥80% F细胞(近全细胞性),近半数达≥90% F细胞(全细胞性)。
- 更早启动治疗和更好依从性与高F细胞反应相关。
核心结论
- 以预测MTD起始的个体化药代动力学指导羟基脲方案可使SCA患儿获得持续近全细胞性或全细胞性HbF表达。
研究设计与样本
- 研究纳入接受个体化药代动力学指导羟基脲治疗的SCA患儿,起始剂量为预测MTD,临床试验注册号NCT02286154。
主要发现
- 观察到持续HbF诱导(平均>30%)长达6年,且不依赖HbF表达的遗传决定因素。
- 近70%患者F细胞≥80%(近全细胞性),近半数患者F细胞≥90%(全细胞性)。
- 平均HbF/F细胞含量约12 pg。
- 更早启动治疗和更好用药依从性与高F细胞反应相关。
关键数值与推荐
- 持续HbF诱导平均>30%,长达6年。
- 近70%患者F细胞≥80%,近半数患者F细胞≥90%。
- 平均HbF/F细胞含量约12 pg。
临床怎么用
- 对SCA患儿可考虑早期启动羟基脲,采用个体化药代动力学指导的预测MTD起始剂量以追求近全细胞性或全细胞性HbF诱导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxyurea (hydroxycarbamide) is an effective treatment for sickle cell anaemia (SCA), but clinical responses depend primarily upon the degree of fetal haemoglobin (HbF) induction and the heterogeneity of HbF expression across erythrocytes. The number and characteristics of HbF-containing cells (F-cells) are not assessed by traditional HbF measurements. Conventional hydroxyurea dosing (e.g. fixed doses or low starting doses with stepwise escalation) produces a moderate heterocellular HbF induction, but haemolysis and clinical complications continue. Robust, pancellular HbF induction is needed to minimise or fully inhibit polymerisation of sickle haemoglobin. We treated children with hydroxyurea using an individualised, pharmacokinetics-guided regimen starting at predicted maximum tolerated dose (MTD). We observed sustained HbF induction (mean >30%) for up to 6 years, which was not dependent on genetic determinants of HbF expression. Nearly 70% of patients had ≥80% F-cells (near-pancellular), and almost half had ≥90% F-cells (pancellular). The mean HbF/F-cell content was ~12 pg. Earlier age of initiation and better medication adherence were associated with high F-cell responses. In summary, early initiation of hydroxyurea using pharmacokinetics-guided starting doses at predicted MTD can achieve sustained near-pancellular or pancellular HbF expression and should be considered an achievable goal for children with SCA treated with hydroxyurea at optimal doses. Clinical trial registration number: NCT02286154 (clinicaltrials.gov).
引用
- Quinn CT, Niss O, Dong M, et al. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. Br J Haematol. 2021. PMID: 34227124. doi:10.1111/bjh.17663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。